Log in to save to my catalogue

Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2...

Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_35616d559f1c44c9926976371af60411

Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age – a multicenter retrospective study

About this item

Full title

Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age – a multicenter retrospective study

Publisher

England: BioMed Central Ltd

Journal title

Orphanet journal of rare diseases, 2019-05, Vol.14 (1), p.96-96, Article 96

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

Tuberous sclerosis complex (TSC) is a multisystem disease with prominent neurologic manifestations such as epilepsy, cognitive impairment and autism spectrum disorder. mTOR inhibitors have successfully been used to treat TSC-related manifestations in older children and adults. However, data on their safety and efficacy in infants and young children...

Alternative Titles

Full title

Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age – a multicenter retrospective study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_35616d559f1c44c9926976371af60411

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_35616d559f1c44c9926976371af60411

Other Identifiers

ISSN

1750-1172

E-ISSN

1750-1172

DOI

10.1186/s13023-019-1077-6

How to access this item